Dublin, Feb. 06, 2019 (GLOBE NEWSWIRE) -- The "Global Proteomics Partnering Terms and Agreements 2010-2018" report has been added to ResearchAndMarkets.com's offering.

The Global Proteomics Partnering Terms and Agreements 2010 to 2018 report provides an understanding and access to the Proteomics partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter Proteomics partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors Proteomics technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains links to online copies of actual Proteomics deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

Report scope

• Trends in Proteomics dealmaking in the biopharma industry since 2010
• Analysis of Proteomics deal structure
• Access to headline, upfront, milestone and royalty data
• Case studies of real-life Proteomics deals
• Access to over 200 Proteomics deal records and contract documents where available
• The leading antibody deals by value since 2010
• Most active Proteomics dealmakers since 2010
• The leading Proteomics partnering resources

Available contracts are listed by:

• Company A-Z
• Headline value
• Stage of development at signing
• Deal component type
• Specific therapy and technology target

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Proteomics dealmaking

2.1. Introduction
2.2. Proteomics partnering over the years
2.3. Most active Proteomics dealmakers
2.4. Proteomics partnering by deal type
2.5. Proteomics partnering by therapy area
2.6. Proteomics partnering by industry sector
2.7. Deal terms for Proteomics partnering
2.7.1 Proteomics partnering headline values
2.7.2 Proteomics deal upfront payments
2.7.3 Proteomics deal milestone payments
2.7.4 Proteomics royalty rates
2.8. The anatomy of an Proteomics deal
2.8. a. Case study 1: RRD International & Dipexium Pharmaceuticals
2.8.b. Case study 2: Hospira & Cempra Pharmaceutical
2.8.c. Case study 3: Astellas & Optimer Pharmaceuticals

Chapter 3 - Leading Proteomics deals

3.1. Introduction
3.2. Top Proteomics deals by value

Chapter 4 - Most active Proteomics dealmakers

4.1. Introduction
4.2. Most active Proteomics dealmakers
4.3. Most active Proteomics partnering company profiles

Chapter 5 - Proteomics contracts dealmaking directory

5.1. Introduction
5.2. Proteomics contracts dealmaking directory

Chapter 6 - Proteomics dealmaking by technology type

Chapter 7 - Partnering resource center

7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking

Appendices

Appendix 1 - Proteomics deals by company A-Z
Appendix 2 - Proteomics deals by stage of development
Appendix 3 - Proteomics deals by deal type
Appendix 4 - Proteomics deals by therapy area
Appendix 5 - Deal type definitions

For more information about this report visit https://www.researchandmarkets.com/research/l4xhzm/global_proteomics?w=12

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Press Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
Related Topics: Proteomics